{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:57:54Z","timestamp":1791464274318,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejso.2019.06.023","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T12:42:54Z","timestamp":1560429774000},"page":"2096-2102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases"],"prefix":"10.1016","volume":"45","author":[{"given":"Valerio","family":"Gallotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"D\u2019Indinosante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Capoluongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino Maria","family":"De Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ardito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Giuliante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Margreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Ferrandina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejso.2019.06.023_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ejso.2019.06.023_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Participants of the fifth ovarian cancer consensus conference. Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2019.06.023_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.016","article-title":"Histotype classification of ovarian carcinoma: a comparison of approaches","volume":"151","author":"Peres","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2019.06.023_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-018-0572-7","article-title":"Using PARP inhibitors in the treatment of patients with ovarian cancer","volume":"19","author":"Kurnit","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2019.06.023_bib5","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2006.03.025","article-title":"Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations","volume":"42","author":"Ferrandina","year":"2006","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2019.06.023_bib6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"SOLO2\/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ejso.2019.06.023_bib7","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejso.2019.06.023_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2016.04.537","article-title":"Surgical management of recurrent ovarian cancer","volume":"142","author":"Suh","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2019.06.023_bib9","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"2","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejso.2019.06.023_bib10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2019.06.023_bib11","series-title":"2. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. Abs.5501","author":"du Bois","year":"2017"},{"issue":"1","key":"10.1016\/j.ejso.2019.06.023_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/gyno.1997.4727","article-title":"Hepatic resection for metastatic gynecologic carcinomas","volume":"66","author":"Chi","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2019.06.023_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2003.07.005","article-title":"Resection of recurrent ovarian or fallopian tube carcinoma involving the liver","volume":"91","author":"Yoon","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2019.06.023_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/13651820500472119","article-title":"Hepatic resection for metachronous metastases from ovarian carcinoma","volume":"8","author":"Bosquet","year":"2006","journal-title":"HPB (Oxford)"},{"issue":"1","key":"10.1016\/j.ejso.2019.06.023_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-8258(03)00004-0","article-title":"Hepatic resection for metachronous metastases from ovarian carcinoma","volume":"89","author":"Merideth","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2019.06.023_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.amjsurg.2007.12.012","article-title":"Hepatic resection for recurrent metastatic ovarian cancer","volume":"195","author":"Abood","year":"2008","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.ejso.2019.06.023_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1015-9584(10)60014-0","article-title":"Surgery for isolated liver metastasis of ovarian cancer","volume":"33","author":"Pekmezci","year":"2010","journal-title":"Asian J Surg"},{"issue":"5","key":"10.1016\/j.ejso.2019.06.023_bib18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00404-010-1750-4","article-title":"Hepaticresection as part of secondary cytoreductive surgery for recurrent ovarian cancer involving the liver","volume":"284","author":"Roh","year":"2011","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.ejso.2019.06.023_bib19","first-page":"182","article-title":"Hepatic resection is safe for metachronous hepatic metastases from ovarian cancer","volume":"9","author":"Niu","year":"2012","journal-title":"Cancer Biol Med"},{"issue":"1","key":"10.1016\/j.ejso.2019.06.023_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/IGC.0000000000000026","article-title":"The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer","volume":"24","author":"Kolev","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejso.2019.06.023_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12957-015-0652-0","article-title":"Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit","volume":"13","author":"Bacalbasa","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2019.06.023_bib22","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(09)70081-6","article-title":"Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease","volume":"10","author":"Carpizo","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2019.06.023_bib23","first-page":"524","article-title":"Association Fran\u00e7aise de Chirurgie, Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model","volume":"244","author":"Adam","year":"2006","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.ejso.2019.06.023_bib24","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1245\/s10434-018-6700-6","article-title":"BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study","volume":"25","author":"Marchetti","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2019.06.023_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ejso.2019.06.023_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2017.08.004","article-title":"Guidance statement on BRCA1\/2 tumor testing in ovarian cancer patients","volume":"44","author":"Capoluongo","year":"2017","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2019.06.023_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00268-011-1074-y","article-title":"The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma","volume":"35","author":"Kamel","year":"2011","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.ejso.2019.06.023_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00000658-199907000-00005","article-title":"Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography","volume":"230","author":"Rahusen","year":"1999","journal-title":"Ann Surg"},{"issue":"14","key":"10.1016\/j.ejso.2019.06.023_bib29","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.ejso.2019.06.023_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2019.06.023_bib31","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2019.06.023_bib32","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2147\/OTT.S102569","article-title":"Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer","volume":"10","author":"Hollis","year":"2017","journal-title":"OncoTargets Ther"},{"issue":"7","key":"10.1016\/j.ejso.2019.06.023_bib33","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00432-015-2090-3","article-title":"Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer","volume":"142","author":"Gasparri","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2019.06.023_bib34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jmig.2017.10.024","article-title":"Secondary laparoscopic cytoreduction in recurrent ovarian cancer: a large, single-institution experience","volume":"25","author":"Gallotta","year":"2018","journal-title":"J Minim Invasive Gynecol"},{"issue":"11","key":"10.1016\/j.ejso.2019.06.023_bib35","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1245\/s10434-017-6005-1","article-title":"Hepatoceliac lymph node involvement in advanced ovarian cancer patients: prognostic role and clinical considerations","volume":"24","author":"Gallotta","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2019.06.023_bib36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/SLA.0b013e3181bc789c","article-title":"Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes","volume":"250","author":"Nguyen","year":"2009","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.ejso.2019.06.023_bib37","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00464-013-3390-9","article-title":"Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience","volume":"28","author":"Gallotta","year":"2014","journal-title":"Surg Endosc"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319305177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798319305177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T16:07:29Z","timestamp":1755274049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798319305177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0748798319305177"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2019.06.023","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2019.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}